The PE Ratio as of December 2024 (TTM) for Cadrenal Therapeutics, Inc. Common Stock (CVKD) is -2.19

According to Cadrenal Therapeutics, Inc. Common Stock’s latest financial reports and current stock price. The company's current PE Ratio is -2.19. This represents a change of 47.43% compared to the average of -1.49 of the last 4 quarters.

Cadrenal Therapeutics, Inc. Common Stock (CVKD) Historical PE Ratio (quarterly & annually)

How has CVKD PE Ratio performed in the past?

The mean historical PE Ratio of Cadrenal Therapeutics, Inc. Common Stock over the last ten years is -4.15. The current -2.19 PE Ratio has changed 5.18% with respect to the historical average. Over the past ten years (40 quarters), CVKD's PE Ratio was at its highest in in the June 2024 quarter at -0.78. The PE Ratio was at its lowest in in the March 2022 quarter at -1008.80.

Cadrenal Therapeutics, Inc. Common Stock (CVKD) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Cadrenal Therapeutics, Inc. Common Stock PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Cadrenal Therapeutics, Inc. Common Stock (CVKD) Average PE Ratio

How has CVKD PE Ratio performed in the past?

The current PE Ratio of Cadrenal Therapeutics, Inc. Common Stock (CVKD) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Cadrenal Therapeutics, Inc. Common Stock (CVKD) PE Ratio vs. Peers

How is CVKD’s PE Ratio compared to its peers?

Cadrenal Therapeutics, Inc. Common Stock’s PE Ratio is greater than Mineralys Therapeutics, Inc. (-4.16), greater than Structure Therapeutics Inc. (-12.61), greater than Centessa Pharmaceuticals plc (-12.16), greater than Nuvectis Pharma, Inc. (-4.14), less than Senti Biosciences, Inc. (-0.27), greater than ZIVO Bioscience, Inc. (-5.50), greater than Foghorn Therapeutics Inc. (-3.45), less than Quoin Pharmaceuticals, Ltd. (-0.28), less than Ikena Oncology, Inc. (-1.24), less than Enochian Biosciences, Inc. (-1.98), less than Eliem Therapeutics, Inc. (0), less than HCW Biologics Inc. (-0.40), greater than Exicure, Inc. (-8.14), less than Cingulate Inc. (-0.00), less than SAB Biotherapeutics, Inc. (-0.83), greater than Anebulo Pharmaceuticals, Inc. (-5.30), less than Monopar Therapeutics Inc. (-0.59), less than AN2 Therapeutics, Inc. (-0.67), greater than Miromatrix Medical Inc. (-7.13), less than Inhibikase Therapeutics, Inc. (-1.34), less than PMV Pharmaceuticals, Inc. (-1.47),

Build a custom stock screener for Cadrenal Therapeutics, Inc. Common Stock (CVKD) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cadrenal Therapeutics, Inc. Common Stock using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cadrenal Therapeutics, Inc. Common Stock (CVKD) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cadrenal Therapeutics, Inc. Common Stock or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.